Browse the corpus

Cyanocobalamin is a synthetic compound of vitamin B12 used to treat vitamin deficiencies. Chemically, cyanocobalamin is classified as a "corrinoid," representing a crystallizable cobalt complex. The name "cyanocobalamin" is derived from including a cyanide group within the molecule. Cyanocobalamin is approved by the United States Food and Drug Administration (FDA) for pernicious anemia, malabsorption, atrophic gastritis, gastrectomy, Helicobacter pylori infection, and other conditions. Vitamin B12 facilitates several methylation reactions within the body. Methylcobalamin serves as a cofactor in the conversion of homocysteine to methionine in the body. Furthermore, in the form of adenosylcobalamin, the vitamin is crucial in converting methylmalonyl-coenzyme A (CoA) to succinyl-CoA. Both of these reactions are essential for cell division and growth. This activity provides a comprehensive review of cyanocobalamin, covering the indications, mechanism of action, adverse event profile, contraindications, and relevant interactions, as a valuable agent managing vitamin B12 deficiencies. This review is particularly relevant for interprofessional healthcare teams who care for patients with indicated conditions to enhance long-term outcomes. Objectives: Identify patients with vitamin B12 deficiencies who may benefit from cyanocobalamin therapy based on clinical presentations, medical history, and diagnostic findings. Implement evidence-based guidelines into clinical practice to effectively prescribe and administer cyanocobalamin for different vitamin B12 deficiency disorders, considering optimal routes of administration. Select appropriate cyanocobalamin formulations and dosages based on patient characteristics, response to therapy, and the specific indications for vitamin B12 supplementation. Collaborate with other healthcare professionals to ensure a multidisciplinary approach in managing complex cases of vitamin B12 deficiencies, incorporating diverse perspectives for comprehensive care. Access free multiple choice questions on this topic.

Cyanocobalamin secretion is usually in bile. With higher doses of cyanocobalamin, secretion undergoes rapid elimination in the urine. No overdosage occurs with cyanocobalamin. There is no antidote to vitamin B12.

Cyanocobalamin treats a variety of conditions related to vitamin B12 deficiency. The interprofessional team, including clinicians, nurses, pharmacists, and nutritionists, must coordinate activities to manage the condition. Early detection will prevent severe and permanent complications, as prolonged vitamin B12 deficiency may lead to permanent degenerative spinal cord lesions.[37] Due to the risk of hypokalemia early in treatment, electrolytes should be measured during follow-up visits, which require rigorous lab review after the office visit. Clinicians manage surveillance so as not to miss any abnormality. This is where all interprofessional team members can engage in coordinated activity and open communication regarding the patient's condition and response to treatment so that everyone involved operates from the same information base, driving better patient outcomes. With several completely unrelated causes of this deficiency, a clinician is responsible for identifying the probable cause and tailoring therapy and further management of various conditions for different individuals depending on a case-to-case basis.[38] The involvement of specialists may prove necessary in several instances. For example, A patient with D latum infection may need follow-up with an infectious disease specialist. A patient with a dietary deficiency may need to see a dietician or a nutritionist. A patient with H pylori infection, atrophic gastritis, malabsorption, pancreatic insufficiency, or Crohn disease may need to see a gastroenterologist or a surgeon. A patient with malignancy of the bowel/pancreas may need oncology follow-up. Due to the correlation of pernicious anemia with carcinoma of the stomach, a gastroenterology workup may be recommended.[36] Vitamin B12 deficiency suppresses the signs of polycythemia vera, which may be unmasked after treatment—vitamin B12 deficiency with a normal MCV due to co-existent thalassemia/iron deficiency anemia. Hence, a hematologist may guide further therapy. Due to the possibility of hypersensitivity to the drug, the clinician administers it with necessary precautions and performs an intradermal test if an allergy is suspected. Education about allergic reactions and other adverse effects is necessary for optimal outcomes and the prevention of anaphylactic shock.